is still the gold standard method for detecting mutations. This method is able to detect all mutations in the region of interest, but it requires a high allele frequency of mutation (10–30%) to meet the level of detection, suggesting that it may not be appropriate for clinical...
SNARE-enabled transport is a vulnerability of KRAS-driven cancer.aSurvival of KRAS-mutant pancreatic adenocarcinoma patients depending on mutation and expression status of SNAP23 and VAMP3 (n = 186).bSurvival of KRAS-mutant pancreatic adenocarcinoma patients depending on mutation and expression sta...
HRAS G12C or NRAS G12C mutation in a subject in need thereof, the method comprising: determining if the subject has a KRAS, HRAS or NRAS G12C mutation; and if the subject is determined to have the KRAS, HRAS or NRAS G12C mutation, then administering to the subject a therapeutically ...
by N-acetyltransferase (NAT). N-acetylation is very common in eukaryotes but rarely occurs in prokaryotes22. The functional importance of this modification has been suggested that it neutralizes positive charge associated with the free-amino group at the N-terminus, and thereby efficiently blocks it...
在结直肠癌循环肿瘤细胞中KRAS和PIK3CA的突变以及EGFR异质性的研究 Studyintroduction •美国国家癌症综合治疗联盟（NCCN）《结直肠癌临床实践指南》(2019)明确指出：(1)所有转移性结直肠癌患者都应检测KRAS基因状态；(2)只有KRAS野生型患者才建议接受EGFR抑制剂（如爱必妥和帕尼单抗）治疗。NCCN《非小细胞肺癌临床实践...
“KRAS is among the most prevalent mutations in cancer and KRAS G12C is the most common KRAS mutation in patients with non-small cell lung cancer,” said Dr. Marjorie Green, senior vice president and...
We then queried the Lung Adenocarcinoma dataset for LKB1 mutant tumors, breaking the dataset into an Altered group with mutation in LKB1 (STK11) or an Unaltered group with functional LKB1. As expected, the LKB1-dependent phosphorylation of AMPK at T172 was significantly reduced in LKB1 mutant tu...
[84]. These evidences are related to the positive correlation betweenKRASmutation and PD-L1 expression in lung adenocarcinoma, which represents the innate immune resistance. PD-L1 seems to be up-regulated in models of NSCLC with mutation in theKRASoncogene through p-ERK, hence PD-1 inhibitors ...
A better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer. While these therapies hold great promise,...
Klinikum Bayreuth dataset.The results of KRAS mutation in these ten patients were all positive. In this group, there were three males and seven females, the median age was 68.5 years (range 58 to 85 years), and all of them had a history of smoking. ...